<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1396">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05142982</url>
  </required_header>
  <id_info>
    <org_study_id>PROsem</org_study_id>
    <nct_id>NCT05142982</nct_id>
  </id_info>
  <brief_title>Radiotherapy vs Observation for Post Chemotherapy Residual Mass in Advanced Seminoma</brief_title>
  <official_title>FDG PET-CT Based Risk Adapted Radiotherapy vs Observation for Post Chemotherapy Residual Mass in Advanced Seminoma: A Prospective Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tata Memorial Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tata Memorial Centre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Testicular tumors account for 1% of all cancers in males and germ cell tumors comprise 95% of&#xD;
      all testicular cancers. Seminomas consist of around 50% of cases. However,adequate&#xD;
      information is not there as 60- 80% residual disease is seen even after with the standard&#xD;
      management of chemotherapy.&#xD;
&#xD;
      With the advent of functional imaging there was hope that it could aid in more accurately&#xD;
      targeting these tumors to systematically evaluate the role of PET-CT imaging in identifying&#xD;
      patients diagnosed with stage IIB-IIIC seminomatous germ cell tumor, with residual visible&#xD;
      tumor post chemotherapy who would benefit with loco regional radiotherapy.&#xD;
&#xD;
      The therapeutic research in Seminomashas been relatively slow and such structured studies can&#xD;
      allow analysis of large number of patients to report on acute and late effect of treatment&#xD;
      outcomes using CTCAE and QOL (EORTC QLQ C-30) in these cancers. We hope that we will get help&#xD;
      in identifying thrust areas for future research through this study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 15, 2021</start_date>
  <completion_date type="Anticipated">December 15, 2029</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2029</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival(PFS)</measure>
    <time_frame>2 years</time_frame>
    <description>• Progression free survival (PFS) is defined as the time period from the date of enrolment in the study till the first observation of disease progression at any site, or death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Locoregional control (LRC)</measure>
    <time_frame>2 years</time_frame>
    <description>• Locoregional control (LRC) defined as the time period from the date of enrolment in the study till the first observation of disease progression locally and/or in the regional lymph nodes, or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>2 years</time_frame>
    <description>• Overall survival (OS) defined as the time period from the date of enrolment in the study till the date of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Second-line salvage therapy-free survival</measure>
    <time_frame>2 years</time_frame>
    <description>• Second-line salvage therapy-free survival defined as the time period from the date of enrolment in the study till date of starting second-line chemotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute radiation toxicity</measure>
    <time_frame>2 years</time_frame>
    <description>Incidence of Acute radiation toxicity will be defined as any toxicity within 90 days post RT using RTOG and CTCAE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late radiation toxicity</measure>
    <time_frame>2 years</time_frame>
    <description>Incidence of late radiation toxicity defined as any toxicity after 90 days of post RT using RTOG and CTCAE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported quality of life (QOL)</measure>
    <time_frame>2 years</time_frame>
    <description>Patient-reported quality of life (QOL) will be assessed using the EORTC QLQ-C30 questionnaire's validated translations in English, Hindi, and Marathi.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Seminoma</condition>
  <arm_group>
    <arm_group_label>Radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to the test arm will undergo radiotherapy to the residual mass. Patients will be stratified by the size of the residual mass in shortest dimension being &lt;3 cm or &gt; 3 cm.A dose of 30-36 Gy in conventional fractionation of 1.8-2.0 Gy per fraction using 3-dimensional conformal technique. Radiotherapy will be delivered five days a week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients randomized to the standard arm will be observed and the status of residual mass monitored with an FDG PETCT scan done at three to six monthly intervals.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>A dose of 30-36 Gy in conventional fractionation of 1.8-2.0 Gy per fraction using 3-dimensional conformal technique. Radiotherapy will be delivered five days a week.</description>
    <arm_group_label>Radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histological diagnosis of classical seminoma&#xD;
&#xD;
          2. Primary site - testis, mediastinum or retroperitoneum&#xD;
&#xD;
          3. Stage IIB-IIIC (AJCC 8th edition)&#xD;
&#xD;
          4. Age&gt;18 years&#xD;
&#xD;
          5. Karnofsky Performance Status at least 70&#xD;
&#xD;
          6. A response assessment FDG PETCT scan done at least twelve weeks after the first line&#xD;
             chemotherapy, showing a persistent measurable residual mass&#xD;
&#xD;
          7. Patient willing and reliable for follow up and QOL.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Histology other than classical seminoma&#xD;
&#xD;
          2. Non completion of planned first-line chemotherapy&#xD;
&#xD;
          3. Prior history of radiotherapy to the involved region&#xD;
&#xD;
          4. Inability to deliver adequate radiotherapy dose safely based on assessment by&#xD;
             radiation oncologist&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Tata Memorial Centre</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>410210</zip>
        <country>India</country>
      </address>
    </facility>
    <contact>
      <last_name>Vedang Murthy</last_name>
      <email>vmurthy@actrec.gov.in</email>
    </contact>
    <contact_backup>
      <last_name>Gitanjali Panigrahi</last_name>
      <phone>02224175000</phone>
      <phone_ext>5097</phone_ext>
      <email>urooncorttrial@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Dr Vedang Murthy</name>
      <address>
        <city>Navi-Mumbai</city>
        <state>Maharashtra</state>
        <zip>410210</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>November 15, 2021</study_first_submitted>
  <study_first_submitted_qc>December 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2021</study_first_posted>
  <last_update_submitted>December 2, 2021</last_update_submitted>
  <last_update_submitted_qc>December 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tata Memorial Centre</investigator_affiliation>
    <investigator_full_name>Dr Vedang Murthy</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>FDG-PET CT, radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Seminoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

